Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 7/20 | 0.45 |
| ▸ | MYC | P01106 | 12/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 3/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.38 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.38 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2372056 | 1.00 | CFTR (0.45) | CFTRMYCNR4A1ESR1ALOX15 | |
| SCHEMBL13518970 | 0.92 | CFTR (0.42) | CFTRMYCNR4A1HSD17B10 | |
| SCHEMBL2372633 | 0.86 | CFTR (0.45) | CFTRMYCHSD17B10 | |
| SCHEMBL29699381 | 0.86 | CFTR (0.45) | CFTRMYCHSD17B10 | |
| SCHEMBL2372656 | 0.85 | MYC (0.44) | CFTRMYCNR4A1ESR1ALOX15 | |
| SCHEMBL29699221 | 0.85 | MYC (0.44) | CFTRMYCNR4A1ESR1ALOX15 | |
| SCHEMBL2373031 | 0.82 | MYC (0.44) | CFTRMYCNR4A1ESR1ALOX15 | |
| SCHEMBL12295762 | 0.81 | CFTR (0.40) | CFTRMYCNR4A1GRIA1GRIA2 | |
| SCHEMBL28800852 | 0.81 | AGBL2 (0.43) | CFTRMYCNR4A1ESR1ALOX15 | |
| SCHEMBL2372906 | 0.79 | CFTR (0.44) | CFTRMYCESR1ALOX15PTPN7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3980121-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF, COPD, AND BRONCHIECTASIS | Novartis AG (CH) | 2022-04-13 | — | — | EP | disclosed |